Developmental variations in metabolic capacity of flavin-containing mono-oxygenase 3 in childhood

British Journal of Clinical Pharmacology

Volumn 71, Issue 4, 2011, Pages 585-591

  Shimizu, Makiko ^a   Denton, Travis ^b   Kozono, Marie ^a   Cashman, John R ^b   Leeder, J Steven ^c   Yamazaki, Hiroshi ^a  

^a SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^b HUMAN BIOMOLECULAR RESEARCH INSTITUTE   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

FMO3; Infant; Neonate; Trimethylamine; Trimethylaminuria

Indexed keywords

CYTOCHROME P450 2D6; QUERCETIN; TRIMETHYLAMINE;

ARTICLE; CATALYSIS; CHILD; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HUMAN; IMMUNOCHEMISTRY; IN VITRO STUDY; INFANT; LIVER MICROSOME; MALE; METABOLIC CAPACITY; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; URINALYSIS;

AGE FACTORS; ANTIOXIDANTS; CHILD DEVELOPMENT; FEMALE; GENE EXPRESSION; HUMANS; INFANT; INFANT, NEWBORN; MALE; METABOLISM, INBORN ERRORS; METHYLAMINES; MICROSOMES, LIVER; OXYGENASES; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS;

EID: 79952597193     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03876.x     Document Type: Article

References (23)

1. Cashman JR, Zhang J. Human flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol 2006; 46: 65-100.
2. Hernandez D, Janmohamed A, Chandan P, Phillips IR, Shephard EA. Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. Pharmacogenetics 2004; 14: 117-30.
3. Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, Hines RN. Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res 2002; 51: 236-43.
4. Zhang J, Cashman JR. Quantitive analysis of FMO gene mRNA levels in human tissues. Drug Metab Dispos 2006; 34: 19-26.
5. Shimizu M, Tomioka S, Murayama N, Yamazaki H. Missense and nonsense mutations of the flavin-containing monooxygenase 3 gene in a Japanese cohort. Drug Metab Pharmacokinet 2007; 22: 61-4.
6. Yamazaki H, Shimizu M. Genetic polymorphism of the flavin-containing monooxygenase 3 (FMO3) associated with trimethylaminuria (fish odor syndrome): observations from Japanese patients. Curr Drug Metab 2007; 8: 487-91.
7. Yamazaki H, Fujieda M, Cashman JR, Kamataki T. Mild trimethylaminuria observed in a Japanese cohort with liver damage. Am J Med 2005; 118: 803-5.
8. Shimizu M, Cashman JR, Yamazaki H. Transient trimethylaminuria related to menstruation. BMC Med Genet 2007; 8: 2.
9. Hines RN. Developmental and tissue-specific expression of human flavin-containing monooxygenases 1 and 3. Expert Opin Drug Metab Toxicol 2006; 2: 41-9.
10. Blake MJ, Gaedigk A, Pearce RE, Bomgaars LR, Christensen ML, Stowe C, James LP, Wilson JT, Kearns GL, Leeder JS. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther 2007; 81: 510-6.
11. Yamazaki H, Fujieda M, Togashi M, Saito T, Preti G, Cashman JR, Kamataki T. Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of trimethylamine in Japanese trimethylaminuria patients. Life Sci 2004; 74: 2739-47.
12. Yamazaki H, Fujita H, Gunji T, Zhang J, Kamataki T, Cashman JR, Shimizu M. Stop codon mutations in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population. Mol Genet Metab 2007; 90: 58-63.
13. Allerston CK, Shimizu M, Fujieda M, Shephard EA, Yamazaki H, Phillips IR. Molecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene (FMO3). Pharmacogenet Genomics 2007; 17: 827-39.
14. Nagashima S, Shimizu M, Yano H, Murayama N, Kumai T, Kobayashi S, Guengerich FP, Yamazaki H. Inter-individual variation in flavin-containing monooxygenase 3 in livers from Japanese: correlation with hepatic transcription factors. Drug Metab Pharmacokinet 2009; 24: 218-25.
15. Fujieda M, Yamazaki H, Togashi M, Saito T, Kamataki T. Two novel single nucleotide polymorphisms (SNPs) of the FMO3 gene in Japanese. Drug Metab Pharmacokinet 2003; 18: 333-5.
16. Kubota M, Nakamoto Y, Nakayama K, Ujjin P, Satarug S, Mushiroda T, Yokoi T, Funayama M, Kamataki T. A mutation in the flavin-containing monooxygenase 3 gene and its effects on catalytic activity for N-oxidation of trimethylamine in vitro. Drug Metab Pharmacokinet 2002; 17: 207-13.
17. Shimizu M, Yano H, Nagashima S, Murayama N, Zhang J, Cashman JR, Yamazaki H. Effect of genetic variants of the human flavin-containing monooxygenase 3 (FMO3) on N- and S-oxygenation activities. Drug Metab Dispos 2007; 35: 328-30.
18. Lattard V, Zhang J, Tran Q, Furnes B, Schlenk D, Cashman JR. Two new polymorphisms of the FMO3 gene in Caucasian and African-American populations: comparative genetic and functional studies. Drug Metab Dispos 2003; 31: 854-60.
19. Grothusen A, Hardt J, Brautigam L, Lang D, Böker R. A convenient method to discriminate between cytochrome P450 enzymes and flavin-containing monooxygenases in human liver microsomes. Arch Toxicol 1996; 71: 64-71.
20. Koukouritaki SB, Poch MT, Cabacungan ET, McCarver DG, Hines RN. Discovery of novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polymorphisms and functional analysis of upstream haplotype variants. Mol Pharmacol 2005; 68: 383-92.
21. Lattard V, Zhang J, Cashman JR. Alternative processing events in human FMO genes. Mol Pharmacol 2004; 65: 1517-25.
22. Shimizu M, Murayama N, Nagashima S, Fujieda M, Yamazaki H. Complex mechanism underlying transcriptional control of the haplotyped flavin-containing monooxygenase 3 (FMO3) gene in Japanese: different regulation between mutations in 5'-upstream distal region and common element in proximal region. Drug Metab Pharmacokinet 2008; 23: 54-8.
23. Shimizu M, Kozono M, Murayama N, Yamazaki H. Bonitos with low contents of malodorous trimethylamine as palliative cares for self-reported Japanese trimethylaminuria subjects. Drug Metab Pharmacokinet 2009; 24: 549-52.